Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yellow Fever Vaccine Immunity and Lymph Node Inflammation
NCT04269265Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Jul 2020
- Primary completion
- Oct 2023
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of 17D yellow fever vaccine in yellow fever, sponsored by University of Minnesota. Primary endpoint: Peak Neutralizing Antibody Titer at 18 months. Started Jul 2020; status: completed.
02
Drugs
17D yellow fever vaccine
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT04269265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269265.